High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: Results of a 12-year experience at loma linda university medical center

International Journal of Radiation Oncology Biology Physics

Volumn 86, Issue 5, 2013, Pages 964-968

  Bush, David A ^a   Cheek, Gregory ^b   Zaheer, Salman ^b   Wallen, Jason ^b   Mirshahidi, Hamid ^b   Katerelos, Ari ^a   Grove, Roger ^a   Slater, Jerry D ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEAM RADIATION THERAPY; DISEASE-SPECIFIC SURVIVALS; EARLY-STAGE LUNG CANCERS; FORCED EXPIRATORY VOLUME IN 1; LOMA LINDA UNIVERSITY MEDICAL CENTERS; METHODS AND MATERIALS; MULTI VARIATE ANALYSIS; NON SMALL CELL LUNG CANCER;

BIOLOGICAL ORGANS; DISEASE CONTROL; DISEASES; PROTON BEAMS; TUMORS;

RADIOTHERAPY;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE SPECIFIC SURVIVAL; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYPOFRACTIONATED PROTON BEAM RADIATION THERAPY; INOPERABLE CANCER; LUNG FUNCTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTON THERAPY; RADIATION DOSE; TOXICITY; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DOSE FRACTIONATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROTON THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84880020196     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2013.05.002     Document Type: Article

References (15)

1. C.F. Mountain Revisions in the international system for staging lung cancer Chest 111 1997 1710 1717 (Pubitemid 27260107)
2. D.H. Harpole Jr., J.E. Herndon II, and W.G. Young Jr. Stage I nonsmall cell lung cancer: a multivariate analysis of treatment methods and patterns of recurrence Cancer 76 1995 787 796
3. J.Y. Chang, X. Zhang, and X. Wang Kang Y, Riley B, Bilton S, Mohan R, Komaki R, Cox JD. Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in stage I or stage III non-small-cell lung cancer Int J Radiat Oncol Biol Phys 65 2006 1087 1096
4. R.C. Nichols, S.H. Huh, and B.S. Hoppe Protons safely allow coverage of high-risk nodes for patients with regionally advanced non-small-cell lung cancer Technol Cancer Res Treat 10 2011 317 322
5. X. Zhang, Y. Li, and X. Pan Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study Int J Radiat Oncol Biol Phys 77 2010 357 366
6. N. Mehta, C.R. King, and N. Agazaryan Stereotactic body radiation therapy and 3-dimensional conformal radiotherapy for stage I non-small cell lung cancer: a pooled analysis of biological equivalent dose and local control Pract Radiat Oncol 2 2012 288 295
7. D.A. Bush, J.D. Slater, and B.A. Shin Hypofractionated proton beam radiotherapy for stage I lung cancer Chest 126 2004 1198 1203 (Pubitemid 39391251)
8. R.B. Bonnet, D. Bush, and G.A. Cheek Effects of proton and combined proton/photon beam radiation on pulmonary function in patients with resectable but medically inoperable non-small-cell lung cancer Chest 120 2001 1803 1810 (Pubitemid 34053437)
9. R. Timmerman, R. McGarry, and C. Yiannoutsos Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer J Clin Oncol 24 2006 4833 4839 (Pubitemid 46630909)
10. S.P. Register, X. Zhang, and R. Mohan Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 80 2011 1015 1022
11. M. Okada, W. Nishio, and T. Sakamoto Thorac Cardiovasc Surg 129 2005 87 93
12. R. Rami-Porta, D. Ball, and J. Crowley The IASLC lung cancer staging project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer J Thoracic Oncol 2 2007 593 602 (Pubitemid 47171780)
13. G.V. Scagliotti, U. Pastorino, and J.F. Vansteenkiste Randomized phase II study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer J Clin Oncol 30 2012 172 178
14. G.M. Strauss, J.E. Herndon II, and G.V. Scagliotti Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group study groups J Clin Oncol 26 2008 5043 5051
15. J.Y. Douillard, R. Rosell, and M. De Lena Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomized controlled trial Lancet Oncol 7 2006 719 727 (Pubitemid 44283661)